Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC future for canker sore patch?

This article was originally published in The Tan Sheet

Executive Summary

Oral canker sore delivery vehicle OraDisc A, "which adheres to the disease site and slowly degrades, releasing the drug locally," eventually could be marketed OTC, Access Pharmaceuticals says. Although firm has been in negotiations with "numerous consumer/pharmaceutical organizations globally" to develop OTC version of oral delivery vehicle for amlexanox, details and timing of such a move remain uncertain, Access says. Final Phase III study for Rx version "has commenced and completion is anticipated by the end of 2002," company notes...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094396

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel